Cannabinoid Modulation of Macrophage Function

大麻素对巨噬细胞功能的调节

基本信息

  • 批准号:
    7849045
  • 负责人:
  • 金额:
    $ 28.18万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-06-01 至 2012-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Marijuana is the most widely used illicit drug in the United States. Delta-9-tetrahydrocannabinol (THC), the major psychoactive component in marijuana, has been reported to be immunosuppressive and to alter the functional activities of macrophages. THC and various cannabinoids inhibit macrophage migration and phagocytosis, dampen production of chemokines, alter processing of antigens, down-regulate production of pro-inflammatory cytokines, and alter the systemic balance of cytokines from a Th1 pro-inflammatory to a Th2 anti-inflammatory profile. Now that an endogenous cannabinoid (endocannabinoid) system has been identified as having two receptor types, several signal transduction pathways, three prominent endocannabinoids, and specific pathways for the synthesis, cellular uptake and metabolism of the endocannabinoids, it is our premise that exogenous cannabinoids such as THC alter this endogenous system. Thus, definition of the effects of cannabinoids on macrophage function is important in view of initiatives to use marijuana as a medicinal for treatment of chronic disabling diseases, including AIDS. The objective of this study is to define the role of endogenous and exogenous cannabinoids in the modulation of macrophage function. The central hypothesis to be tested is that endocannabinoids exert their actions through cannabinoid receptors. However, we propose further that while endocannabinoids and exogenous cannabinoids act through these receptors, the consequences of such interactions are distinctive. That is, in contrast to exogenous cannabinoids, the effects of endocannabinoids may be localized and of short duration. This distinction may articulate a mode by which exogenous cannabinoids superimpose effects over the endocannabinoid system. In order to test these hypotheses, three Specific Aims will serve as guidelines to the research. First, it is proposed to define the effects of endocannabinoids on signature functional activities attributed to macrophages when in defined states of activation. The effects of arachidonylethanolamide (anandamide), 2-arachidonylglycerol (2-AG), and noladin ether will be assessed. Second, it is proposed to compare the in vitro effects endocannabinoids to those of THC. Third, it is proposed through a series of select experiments to determine whether in vitro effects are operative in vivo.
描述(申请人提供):大麻是美国使用最广泛的非法药物。delta -9-四氢大麻酚(THC)是大麻中主要的精神活性成分,据报道具有免疫抑制作用,并能改变巨噬细胞的功能活性。四氢大麻酚和各种大麻素抑制巨噬细胞迁移和吞噬,抑制趋化因子的产生,改变抗原的加工,下调促炎细胞因子的产生,并改变细胞因子从Th1促炎到Th2抗炎的系统平衡。既然内源性大麻素(内源性大麻素)系统已经被确定为具有两种受体类型,几种信号转导途径,三种主要的内源性大麻素,以及内源性大麻素的合成,细胞摄取和代谢的特定途径,那么我们的前提是外源性大麻素如四氢大麻酚改变了内源性大麻素系统。因此,大麻素对巨噬细胞功能的影响的定义是重要的,鉴于倡议使用大麻作为药物治疗慢性致残疾病,包括艾滋病。本研究的目的是确定内源性和外源性大麻素在巨噬细胞功能调节中的作用。要测试的中心假设是内源性大麻素通过大麻素受体发挥作用。然而,我们进一步提出,虽然内源性大麻素和外源性大麻素通过这些受体起作用,但这种相互作用的后果是不同的。也就是说,与外源性大麻素相比,内源性大麻素的作用可能是局部的,持续时间短。这种区别可能阐明了外源性大麻素在内源性大麻素系统上叠加效应的模式。为了检验这些假设,三个具体目标将作为研究的指导方针。首先,研究人员提出确定内源性大麻素对巨噬细胞在特定激活状态下的特征功能活动的影响。评估花生四烯基乙醇酰胺(anandamide)、2-花生四烯基甘油(2-AG)和noladin醚的效果。其次,提出比较内源性大麻素与四氢大麻酚的体外作用。第三,提出通过一系列选择性实验来确定体外作用在体内是否有效。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Guy A. Cabral其他文献

Delta(9)-tetrahydrocannabinol selectively increases aspartyl cathepsin D proteolytic activity and impairs lysozyme processing by macrophages.
Delta(9)-四氢大麻酚选择性增加天冬氨酰组织蛋白酶 D 的蛋白水解活性并损害巨噬细胞的溶菌酶加工。
Δ9-Tetrahydrocannabinol Suppresses Macrophage Extrinsic Antiherpesvirus Activity
Δ9-四氢大麻酚抑制巨噬细胞外源性抗疱疹病毒活性
  • DOI:
  • 发表时间:
    1992
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Guy A. Cabral;R. Vásquez
  • 通讯作者:
    R. Vásquez
Effect of δ9-Tetrahydrocannabinol on Herpes Simplex Virus Type 2 Vaginal Infection in the Guinea Pig
δ9-四氢大麻酚对豚鼠单纯疱疹病毒 2 型阴道感染的影响
<em>Acanthamoeba culbertsoni</em>: Analysis of amoebic adhesion and invasion on extracellular matrix components collagen I and laminin-1
  • DOI:
    10.1016/j.exppara.2009.08.004
  • 发表时间:
    2010-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Bruno da Rocha-Azevedo;Melissa Jamerson;Guy A. Cabral;Francine Marciano-Cabral
  • 通讯作者:
    Francine Marciano-Cabral

Guy A. Cabral的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Guy A. Cabral', 18)}}的其他基金

Cannabinoid modulation of microglial response to the HIV protein Tat
大麻素调节小胶质细胞对 HIV 蛋白 Tat 的反应
  • 批准号:
    8225251
  • 财政年份:
    2011
  • 资助金额:
    $ 28.18万
  • 项目类别:
Cannabinoid modulation of microglial response to the HIV protein Tat
大麻素调节小胶质细胞对 HIV 蛋白 Tat 的反应
  • 批准号:
    8134150
  • 财政年份:
    2011
  • 资助金额:
    $ 28.18万
  • 项目类别:
Cannabinoid modulation of microglial response to the HIV protein Tat
大麻素调节小胶质细胞对 HIV 蛋白 Tat 的反应
  • 批准号:
    8426161
  • 财政年份:
    2011
  • 资助金额:
    $ 28.18万
  • 项目类别:
Cannabinoid modulation of microglial response to the HIV protein Tat
大麻素调节小胶质细胞对 HIV 蛋白 Tat 的反应
  • 批准号:
    8618883
  • 财政年份:
    2011
  • 资助金额:
    $ 28.18万
  • 项目类别:
Cannabinoid modulation of microglial response to the HIV protein Tat
大麻素调节小胶质细胞对 HIV 蛋白 Tat 的反应
  • 批准号:
    8810658
  • 财政年份:
    2011
  • 资助金额:
    $ 28.18万
  • 项目类别:
13th-17th Conferences: Drug Abuse, Immune Modulation and AIDS
第13-17届会议:药物滥用、免疫调节和艾滋病
  • 批准号:
    8034336
  • 财政年份:
    2007
  • 资助金额:
    $ 28.18万
  • 项目类别:
Cannabinoid Modulation of Macrophage Function
大麻素对巨噬细胞功能的调节
  • 批准号:
    8074399
  • 财政年份:
    2007
  • 资助金额:
    $ 28.18万
  • 项目类别:
13th-17th Conferences: Drug Abuse, Immune Modulation and AIDS
第13-17届会议:药物滥用、免疫调节和艾滋病
  • 批准号:
    7788089
  • 财政年份:
    2007
  • 资助金额:
    $ 28.18万
  • 项目类别:
13th-17th Conferences: Drug Abuse, Immune Modulation and AIDS
第13-17届会议:药物滥用、免疫调节和艾滋病
  • 批准号:
    7406741
  • 财政年份:
    2007
  • 资助金额:
    $ 28.18万
  • 项目类别:
Cannabinoid Modulation of Macrophage Function
大麻素对巨噬细胞功能的调节
  • 批准号:
    7231154
  • 财政年份:
    2007
  • 资助金额:
    $ 28.18万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 28.18万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 28.18万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 28.18万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 28.18万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 28.18万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 28.18万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 28.18万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 28.18万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 28.18万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 28.18万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了